Bictegravir

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Bictegravir

Examples of brand names: Biktarvy [EU/DE; combination product]

ATC code: J05AR20

Main use (for orientation): HIV

Documented research summary

No direct study of the pair identified; a combination and overlapping enzymes do not constitute clinical evidence. Missing data do not establish safety.

Uncertainties and limitations

The 28 cannabinoid names in the register define the search scope, not 28 clinically studied pairs. Missing data do not establish safety.

No complete new systematic literature search and no independent medical or pharmaceutical professional approval. Note the dosage form and the country of authorisation of the product information.

BIKTARVY combination label; cathepsin A/CES1 activation concerns tenofovir alafenamide, not bictegravir.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names within the documented search scope; no newly established direct finding for the target cannabinoid–drug pair. This must not be equated with 28 clinically studied combinations.

Evidence status: Drug properties from regulatory product information; insufficient data for a direct cannabinoid–drug pair finding in the material assessed.

Mechanism / drug context: Breakdown through CYP3A and UGT1A1.

Type of supporting material: Targeted product-information review and documented individual literature screening; no newly verified direct cannabinoid–drug pair study.

Clinical interpretation: The clinical relevance of a specific cannabinoid combination has not been determined. Drug context may warrant individual professional review, but neither a blanket warning level nor an assurance of safety.

Context: BIKTARVY combination label; cathepsin A/CES1 activation concerns tenofovir alafenamide, not bictegravir.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VE_LABEL_D0328]: Medicine information: properties of the active substance

Statement supported: Breakdown through CYP3A and UGT1A1. Product information: drug context, not evidence for a specific cannabinoid pair or proof of safety.

Source: BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE) TABLET [GILEAD SCIENCES, INC.] [VE_LABEL_D0328]

Source role [C_PROTOCOL_D0328]: Documented search result

Statement supported: Documented title/abstract search scope for the active substance. The link displays the reproducible search query, not a study or proof that no interaction exists. Search date: 23 October 2026. Further search runs are documented in the research dataset.

Source: Reproducible literature search strategy: Bictegravir [C_PROTOCOL_D0328]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The existing individual review, label review and literature screening were read in full; targeted original PK/interaction passages were checked again, but not all product information and search results were newly reviewed in full text. Search findings are limited to the documented V5 search runs.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VE_LABEL_D0328] BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE) TABLET [GILEAD SCIENCES, INC.]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PROTOCOL_D0328] Reproducible literature search strategy: Bictegravir

Original source / bibliographic reference

Authors: Europe PMC; documented search run

Year: 2026

Source type: Search strategy / screening protocol – not an individual study

Source access – 23 October 2026: Research protocol with machine-readable search results – not an individual study.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility